Ozelle to Present O-Cyte 1 Hematology Analyzer at ADLM 2026
Ozelle will unveil O-Cyte 1, its new automated hematology analyzer, at the upcoming Association for Diagnostics & Laboratory Medicine (ADLM) 2026 conference in Anaheim, California, announced in a press release. The device marks the company’s latest step in advancing its AI multiplied by Complete Blood Morphology technology.
O-Cyte 1 combines morphology intelligence, scalable throughput, and a compact design intended for everyday clinical workflows. The analyzer converts cell images into structured morphology data to support consistent interpretation and evidence-based analysis. It can process up to 60 tests per hour as a standalone unit and up to 360 tests per hour when connected in a cascaded configuration.
The system features modular architecture, low-maintenance operation, and a design intended to simplify laboratory processes. Ozelle plans to demonstrate O-Cyte 1 alongside its broader hematology portfolio at Booth 2517 during the ADLM 2026 event, taking place from July 28 to 30 at the Anaheim Convention Center. The company will also offer virtual briefings for partners unable to attend in person.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice Operations Oct 15 Study Tracks 270 Million Clinical AI Queries on OpenEvidence Oct 15 OpenAI Offers US University Labs Free GPT-Rosalind AccessLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Xtalks Plans Webinar on AI for Antibody Process Optimization
MyOme Expands Genomic Risk Platform Worldwide on Oracle Cloud
ACROBiosystems Launches ACRO AIx and Rapid Antibody Validation Service
Othello Raises $8 Million for Live AI Sales Coaching
Danaher Plans AI Autonomous Lab for Antibody Research
Daily AI Brief: the AI news that matters, in your inbox.